Yan ling He

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi request reprint Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes
    Yan ling He
    Arkansas Research, Little Rock, USA
    J Clin Pharmacol 47:127-31. 2007
  2. pmc The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
    Yan ling He
    Novartis Pharmaceuticals, Cambridge, MA, USA
    Br J Clin Pharmacol 65:338-46. 2008
  3. ncbi request reprint Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
    Yan ling He
    Novartis Institutes for BioMedical Research Inc, Cambridge, MA 02139 3584, USA
    Int J Clin Pharmacol Ther 50:237-47. 2012
  4. doi request reprint Clinical pharmacokinetics and pharmacodynamics of vildagliptin
    Yan ling He
    Translational Medicine Translational Science, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Clin Pharmacokinet 51:147-62. 2012
  5. ncbi request reprint Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes
    Y L He
    Novartis Institutes for BioMedical Research Inc, Cambridge, MA, USA
    Int J Clin Pharmacol Ther 48:582-95. 2010
  6. pmc Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes
    Yan ling He
    Translational Sciences Translational Medicine, Novartis Institutes for BioMedical Research Inc, 220 Massachusetts Avenue, Cambridge, MA 02139 3584, USA
    Br J Clin Pharmacol 70:34-42. 2010
  7. ncbi request reprint Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
    Yan ling He
    Novartis Institutes for BioMedical Research Inc, Cambridge, MA 02139 3584, USA
    Curr Med Res Opin 25:1265-72. 2009
  8. ncbi request reprint Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects
    Y L He
    Exploratory Developments, Novartis Institutes for BioMedical Research Inc, Cambridge, MA 02139 3584, USA
    Int J Clin Pharmacol Ther 46:259-67. 2008
  9. ncbi request reprint The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
    Yan ling He
    Exploratory Development, Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139, USA
    Clin Pharmacokinet 46:787-802. 2007
  10. ncbi request reprint Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
    Yan ling He
    DMSc, Exploratory Development, Novartis Institutes of Biomedical Research Inc, 400 Technology Square, Building 605, Rm 811, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:633-41. 2007

Detail Information

Publications18

  1. ncbi request reprint Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes
    Yan ling He
    Arkansas Research, Little Rock, USA
    J Clin Pharmacol 47:127-31. 2007
  2. pmc The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
    Yan ling He
    Novartis Pharmaceuticals, Cambridge, MA, USA
    Br J Clin Pharmacol 65:338-46. 2008
    ..The results suggest that no dose modification is necessary for vildagliptin based on the age, gender, or BMI of a subject...
  3. ncbi request reprint Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
    Yan ling He
    Novartis Institutes for BioMedical Research Inc, Cambridge, MA 02139 3584, USA
    Int J Clin Pharmacol Ther 50:237-47. 2012
    ..To assess the effects of meal timing on the pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin in Japanese patients with Type 2 diabetes...
  4. doi request reprint Clinical pharmacokinetics and pharmacodynamics of vildagliptin
    Yan ling He
    Translational Medicine Translational Science, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Clin Pharmacokinet 51:147-62. 2012
    ....
  5. ncbi request reprint Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes
    Y L He
    Novartis Institutes for BioMedical Research Inc, Cambridge, MA, USA
    Int J Clin Pharmacol Ther 48:582-95. 2010
    ..To assess the pharmacokinetics, pharmacodynamics and safety of vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), in Japanese patients with Type 2 diabetes...
  6. pmc Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes
    Yan ling He
    Translational Sciences Translational Medicine, Novartis Institutes for BioMedical Research Inc, 220 Massachusetts Avenue, Cambridge, MA 02139 3584, USA
    Br J Clin Pharmacol 70:34-42. 2010
    ..The comparative efficacy of vildagliptin under a morning vs. evening dosing regimen has not previously been determined...
  7. ncbi request reprint Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
    Yan ling He
    Novartis Institutes for BioMedical Research Inc, Cambridge, MA 02139 3584, USA
    Curr Med Res Opin 25:1265-72. 2009
    ..This study assessed the effects of coadministration of vildagliptin and metformin on the steady-state pharmacokinetics of each drug...
  8. ncbi request reprint Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects
    Y L He
    Exploratory Developments, Novartis Institutes for BioMedical Research Inc, Cambridge, MA 02139 3584, USA
    Int J Clin Pharmacol Ther 46:259-67. 2008
    ..To assess the bioequivalence of vildagliptin/metformin fixed-dose combination tablets (at doses of 50/500, 50/850 and 50/1,000 mg) with free combination of the individual drugs in healthy subjects...
  9. ncbi request reprint The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
    Yan ling He
    Exploratory Development, Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139, USA
    Clin Pharmacokinet 46:787-802. 2007
    ..The objective of this study was to assess the absolute oral bioavailability of vildagliptin by comparing the systemic exposure after oral and intravenous administration in healthy volunteers...
  10. ncbi request reprint Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
    Yan ling He
    DMSc, Exploratory Development, Novartis Institutes of Biomedical Research Inc, 400 Technology Square, Building 605, Rm 811, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:633-41. 2007
    ..Unlike findings during mixed-meal challenges, vildagliptin increases plasma insulin levels during oral glucose tolerance tests in patients with type 2 diabetes mellitus...
  11. ncbi request reprint Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
    Yan ling He
    Exploratory Development, Novartis Institutes for BioMedical Research, Cambridge, MA 02139 3584, USA
    Curr Med Res Opin 23:1131-8. 2007
    ..This study assessed the effect of multiple doses of vildagliptin 100 mg once daily on warfarin pharmacokinetics and pharmacodynamics following a single 25 mg oral dose of warfarin sodium...
  12. ncbi request reprint Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
    Yan ling He
    Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139 3584, USA
    Clin Pharmacokinet 46:577-88. 2007
    ..Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus...
  13. ncbi request reprint Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers
    Yan ling He
    Exploratory Development DMPK, Novartis Institutes for BioMedical Research, 400 Technology Square, Building 605, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:998-1004. 2007
    ..02 [0.94-1.12]; C(max), 1.08 [0.97-1.20]). In addition, no changes in t(max), t((1/2)), and CL/F were observed for either drug. These results indicate that no dose adjustment is necessary when vildagliptin and digoxin are coadministered...
  14. ncbi request reprint Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects
    Yan ling He
    Exploratory Development DMPK, Novartis Institutes for BioMedical Research, 400 Technology Square, Building 605, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 48:85-95. 2008
    ..No adjustment in dosage based on pharmacokinetic considerations is required should vildagliptin be coadministered with amlodipine, valsartan, or ramipril in patients with type 2 diabetes and hypertension...
  15. doi request reprint Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers
    Yan ling He
    Novartis Institutes for BioMedical Research, Cambridge, MA, USA
    Curr Med Res Opin 24:1703-9. 2008
    ..Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients with type 2 diabetes by increasing alpha- and beta-cell responsiveness to glucose...
  16. ncbi request reprint Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects
    Surya P Ayalasomayajula
    Novartis Pharmaceuticals, East Hanover, NJ 07936, USA
    Curr Med Res Opin 23:2913-20. 2007
    ..There fore, this study was conducted to determine the potential for pharmacokinetic drug-drug interaction between vildagliptin and simvastatin at steady-state...
  17. ncbi request reprint Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
    Gangadhar Sunkara
    One Health Plaza, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    J Clin Pharmacol 47:1152-8. 2007
    ..Vildagliptin displays approximately dose-proportional pharmacokinetics over the 25- to 200-mg dose range, and administration with food has no clinically relevant effect on vildagliptin pharmacokinetics...
  18. ncbi request reprint The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
    Bogdan Balas
    Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Drive, MC 7886, San Antonio, Texas 78229, USA
    J Clin Endocrinol Metab 92:1249-55. 2007
    ..However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration...